Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study (Herhaalde toediening van rhenium-188-HEDP versus radium-223-chloride aan patienten met gemetastaseerd castratie-resistent prostaatcarcinoom; de RaRe studie. )

Trial Profile

Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study (Herhaalde toediening van rhenium-188-HEDP versus radium-223-chloride aan patienten met gemetastaseerd castratie-resistent prostaatcarcinoom; de RaRe studie. )

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Rhenium-188-etidronic acid (Primary) ; Radium 223 chloride
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms RaRe
  • Most Recent Events

    • 16 May 2018 Planned End Date changed from 1 Apr 2024 to 16 May 2024.
    • 16 May 2018 Planned primary completion date changed from 1 Apr 2022 to 16 May 2022.
    • 16 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top